# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Babe Didrikson Zaharias (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML038-SYN
- Date: 2026-03-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Rosalind Vasquez-Thornbury, MD
- Calendar frame: modern shifted

## What we are working on

- Bright red blood with most bowel movements for about three months, stools narrower than before, urgency and a feeling of not having finished; more tired than usual on the course since the end of last season **S**
- A walk-in clinic put the bleeding down to hemorrhoids two months ago and gave her a cream; she is 41, below the age at which screening starts, and was not examined **S**
- She wants to keep competing, and wants to know at once whether whatever this is will mean a colostomy **S**

## Your goals

- Colonoscopy within one week, staging within two weeks, and a tumor board plan before treatment. Target: 2026-03-30. Recorded outcome: Colonoscopy in three days, MRI and CT within nine days, tumor board in eleven days, consultation at two weeks. **S**
- Germline genetic testing with counseling, and an explanation of the mismatch repair deficiency, within four weeks of diagnosis. Target: 2026-04-27. Recorded outcome: Germline panel negative; two somatic MSH2 variants in the tumor explain the deficiency. **S**
- Clinical complete response after six months of dostarlimab, with the rectum and sphincter preserved. Target: 2026-10-05. Recorded outcome: Clinical complete response on MRI, endoscopy and examination after nine doses; watch-and-wait begun. **S**
- Hemoglobin of 12 g/dL or more and ferritin above 30 ng/mL. Target: 2026-10-05. Recorded outcome: Hemoglobin 13.4 g/dL and ferritin 41 ng/mL. **S**
- Back to tournament golf during treatment. Target: 2026-06-29. Recorded outcome: Playing 18 holes and entered in a club competition by the fourth visit. **S**
- TSH within the reference range on thyroid replacement. Target: 2026-08-10. Recorded outcome: TSH 3.1 mIU/L six weeks after levothyroxine began. **S**
- PHQ-9 below 10 throughout treatment. Target: 2026-10-05. Recorded outcome: PHQ-9 between 2 and 6. **S**

## What we agreed to do

- Medical oncology (gastrointestinal) consultation within two weeks, with colorectal surgery, to review the colonoscopy and any biopsy with her and plan staging and treatment if cancer is found. Guideline: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Scott AJ, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol 2024;42(28):3355-3375 (PMID 39116386) (2024) **S**
- Urgent work-up of rectal bleeding with a change in bowel habit and a rectal mass in a woman under 50: colonoscopy with biopsy within days, with mismatch repair testing of any cancer; blood count, ferritin, chemistry and CEA; if cancer is confirmed, rectal-protocol MRI of the pelvis and CT of the chest, abdomen and pelvis; return at once for heavy bleeding, fainting or inability to pass stool. Guideline: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Colorectal Cancer: Screening (JAMA 2021;325(19):1965-1977, PMID 34003218) (2021) **S**
- Oral iron for iron deficiency anemia from blood loss: ferrous sulfate 325 mg on alternate days, a blood count about four weeks after starting, ferritin at about three months, and iron continued for three months after the hemoglobin is normal. Guideline: CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026) **S**
- Germline multigene panel after genetic counseling, because she is under 50 and the tumor is mismatch repair deficient; tumor sequencing for somatic MMR variants if the germline panel is negative; colonoscopy for her first-degree relatives every five years from age 40, or 10 years before the age of her diagnosis if earlier, with Lynch syndrome surveillance only if a germline variant is found. Guideline: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Tung N, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. J Clin Oncol 2024;42(21):2599-2615 (PMID 38759122) (2024); Rex DK, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112(7):1016-1030 (PMID 28555630) (2017) **S**
- Dostarlimab 500 mg intravenously every three weeks for nine doses (six months), with pelvic MRI, flexible sigmoidoscopy and digital rectal examination about every three months; blood count, kidney and liver tests and glucose before each dose and TSH with free T4 every six weeks; teaching about immune-related adverse events with a 24-hour line; hepatitis B, hepatitis C and HIV screening and a pregnancy test first; contraception continued during treatment and for four months after. Guideline: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Scott AJ, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol 2024;42(28):3355-3375 (PMID 39116386) (2024); Cercek A, et al. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med 2022;386(25):2363-2376 (PMID 35660797) (2022); Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020;38(31):3698-3715 (PMID 32716741) (2020) **S**
- If the response is incomplete: chemoradiation and total mesorectal excision, as reviewed with the colorectal surgeon, with stoma site marking and teaching by a wound-ostomy nurse before any operation; fertility and sexual function counseling before any pelvic radiation. Guideline: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Scott AJ, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol 2024;42(28):3355-3375 (PMID 39116386) (2024); Oktay K, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2018;36(19):1994-2001 (PMID 29620997) (2018) **S**
- Levothyroxine for immune-related hypothyroidism, with TSH and free T4 six weeks after starting and every six weeks while on PD-1 blockade; dostarlimab continued. Guideline: Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026) **S**
- Watch-and-wait after a clinical complete response: digital rectal examination and flexible sigmoidoscopy every three to four months and pelvic MRI every six months for two years, CEA every three to six months, CT of the chest, abdomen and pelvis every six to twelve months, colonoscopy at one year, and a written survivorship care plan; surgery at once for any regrowth. Guideline: NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer (current version); summarized in Benson AB, et al. NCCN Guidelines Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(6):366-375 (PMID 39151454) (2026); Cercek A, et al. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med 2025;392(23):2297-2308 (PMID 40293177) (2025); CMID: Clinical Monitoring Intelligence Database, colorectal cancer, hypothyroidism and anemia monographs (2026) **S**
- Distress and depression screening at each visit; plain explanations with written information; attention to sexual health and body image and to her golf, with an exercise plan she sets; she decides who is told and who receives each note. Guideline: Ligibel JA, et al. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. J Clin Oncol 2022;40(22):2491-2507 (PMID 35576506) (2022); Depression and Suicide Risk in Adults: Screening (2023) **S**

## Follow-up

- 2026-03-16: Three months of rectal bleeding, narrower stools and urgency, with tiredness, in a professional golfer of 41: examination, blood tests, and colonoscopy this week **S**
- 2026-03-30: Diagnosis of mismatch repair-deficient low rectal cancer: staging, tumor board plan, medical oncology and colorectal surgery consultation, genetic counseling, and the start of PD-1 blockade **S**
- 2026-04-27: Day 1 of cycle 2 of dostarlimab: early response, immune-related adverse event checks, germline and tumor genetic results, iron and anemia, and golf **S**
- 2026-06-29: Restaging after four doses: pelvic MRI and endoscopy, immune-related hypothyroidism, and the decision to continue PD-1 blockade **S**
- 2026-08-10: Periodic adult preventive visit during immunotherapy **S**
- 2026-10-05: After nine doses: final restaging, clinical complete response, and the watch-and-wait surveillance plan **S**

This teaching document does not replace care from a qualified clinician.
